A drug combination approved last year by the U.S. Food and Drug Administration may have a greater effect for men with melanoma than previously reported, according to a new analysis of clinical trial data.
MRV Research
Melanoma therapy tied to cutaneous adverse events
Shelley Ji Eun Hwang, M.B.B.S., from the University of Sydney, and colleagues reviewed the clinical and histologic information of 82 patients treated with single-agent anti-PD-1 therapy for metastatic melanoma at one institution from May 2012 to February 2015.
IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
Prima BioMed Ltd (ASX: PRR) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therapeutic vaccine has been published in the March 15 edition of the Clinical Cancer Research journal.
Study Links Increased Risk of Melanoma to Use of Sildenafil
Researchers have found that sildenafil — a drug used to treat erectile dysfunction and pulmonary hypertension — is linked to an increased risk of melanoma by promoting cGMP-cGKI signaling cascade. The results, “Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth,” were published in the journal Cell Reports.